Devices and systems for treating the skin using vacuum

Information

  • Patent Grant
  • 9775646
  • Patent Number
    9,775,646
  • Date Filed
    Friday, May 1, 2015
    9 years ago
  • Date Issued
    Tuesday, October 3, 2017
    6 years ago
Abstract
An instrument and technique for the removal of epidermal layers in a controlled manner utilizing a hand-held instrument with a working end that (i) a vacuum aspiration system, (ii) a source for delivery of a sterile fluids or pharmacological agents to the skin; and (iii) a skin interface surface in the working end that has specially shape structure for abrading surface layers of the patient's epidermis as the working end is moved over the patient's skin while at the same time causing rapid penetration of the fluids into the skin for therapeutic purposes. Movement of the working end across the skin causes abrasion of the surface layers in a path over the patient's skin.
Description
BACKGROUND OF THE INVENTION

Field of the Invention


The present invention relates to devices for dermatology and more particularly to a hand-held instrument with a working end that carries (i) a negative pressure aspiration system, (ii) a source for delivery of a sterile fluids to the skin; and (iii) a skin interface surface in the working end that has specially shape structure for abrading surface layers of the patient's epidermis as the working end is moved over the patient's skin while at the same time causing rapid penetration of the fluids into the skin for therapeutic purposes.


Description of the Related Art


Dermatologists and plastic surgeons have used various methods for removing superficial skin layers to cause the growth of new skin layers (i.e., commonly described as skin resurfacing techniques) since the early 1900's. Early skin resurfacing treatments used an acid such as phenol to etch away surface layers of a patient's skin that contained damage to thereafter be replaced by new skin. (The term damage when referring to a skin disorder is herein defined as any cutaneous defect, e.g., including but not limited to rhytides, hyperpigmentation, acne scars, solar elastosis, other dyschromias, stria distensae, seborrheic dermatitus).


Following the removal of surface skin layers at a particular depth, no matter the method of skin removal, the body's natural wound-healing response begins to regenerate the epidermis and underlying wounded skin layers. The new skin layer will then cytologically and architecturally resemble a younger and more normal skin. The range of resurfacing treatments can be divided generally into three categories based on the depth of the skin removal and wound: (i) superficial exfoliations or peels extending into the epidermis, (ii) medium-depth resurfacing treatments extending into the papillary dermis, and (iii) deep resurfacing treatments that remove tissue to the depth of the reticular dermis (see FIGS. 1A-1B).


Modern techniques for skin layer removal include: CO.sub.2 laser resurfacing which falls into the category of a deep resurfacing treatment; Erbium laser resurfacing which generally is considered a medium-depth treatment; mechanical dermabrasion using high-speed abrasive wheels which results in a medium-depth or deep resurfacing treatment; and chemical peels which may range from a superficial to a deep resurfacing treatment, depending on the treatment parameters. A recent treatment, generally called micro-dermabrasion, has been developed that uses an air-pressure source to deliver abrasive particles directly against a patient's skin at high-velocities to abrade away skin layers. Such a micro-dermabrasion modality may be likened to sandblasting albeit at velocities that do no cause excess pain and discomfort to the patient. Micro-dermabrasion as currently practiced falls into the category of a superficial resurfacing treatment.


A superficial exfoliation, peel or abrasion removes some or all of the epidermis (see FIGS. 1A-1B) and thus is suited for treating very light rhytides. Such a superficial exfoliation is not effective in treating many forms of damage to skin. A medium-depth resurfacing treatment that extends into the papillary dermis (see FIG. 1B) can treat many types of damage to skin. Deep resurfacing treatments, such as CO.sub.2 laser treatments, that extend well into the reticular dermis (see FIG. 1B) causes the most significant growth of new skin layers but carry the risk of scarring unless carefully controlled.


It is useful to briefly explain the body's mechanism of actually resurfacing skin in response to the removal of a significant depth of dermal layers. Each of the above-listed depths of treatment disrupts the epidermal barrier, or a deeper dermal barrier (papillary or reticular), which initiates varied levels of the body's wound-healing response. A superficial skin layer removal typically causes a limited wound-healing response, including a transient inflammatory response and limited collagen synthesis within the dermis. In a medium-depth or a deep treatment, the initial inflammatory stage leads to hemostasis through an activated coagulation cascade. Chemotactic factors and fibrin lysis products cause neutrophils and monocytes to appear at the site of the wound. The neutrophils sterilize the wound site and the monocytes convert to macrophages and elaborate growth factors which initiate the next phase of the body's wound-healing response involving granular tissue formation. In this phase, fibroblasts generate a new extracellular matrix, particularly in the papillary and reticuilar dermis, which is sustained by angiogenesis and protected anteriorly by the reforming epithelial layer. The new extracellular matrix is largely composed of collagen fibers (particularly Types I and III) which are laid down in compact parallel arrays (see FIG. 1B). It is largely the collagen fibers that provide the structural integrity of the new skin—and contribute to the appearance of youthful skin.


All of the prevalent types of skin damage (rhytides, solar elastosis effects, hyperpigmentation, acne scars, dyschromias, melasma, stria distensae) manifest common histologic and ultrastructural characteristics, which in particular include disorganized and thinner collagen aggregates, abnormalities in elastic fibers, and abnormal fibroblasts, melanocytes and keratinocytes that disrupt the normal architecture of the dermal layers. It is well recognized that there will be a clinical improvement in the condition and appearance of a patient's skin when a more normal architecture is regenerated by the body's wound-healing response. Of most significance to a clinical improvement is skin is the creation of more dense parallel collagen aggregates with decreased periodicity (spacing between fibrils). The body's wound-healing response is responsible for synthesis of these collagen aggregates. In addition to the body's natural wound healing response, adjunct pharmaceutical treatments that are administered concurrent with, or following, a skin exfoliations can enhance the development of collagen aggregates to provide a more normal dermal architecture in the skin—the result being a more youthful appearing skin.


The deeper skin resurfacing treatments, such as laser ablation, chemical peels and mechanical dermabrasion have drawbacks. The treatments are best used for treatments of a patient's face and may not be suited for treating other portions of a patient's body. For example, laser resurfacing of a patient's neck or decolletage may result in post-treatment pigmentation disorders. All the deep resurfacing treatments are expensive, require anesthetics, and must be performed in a clinical setting. Perhaps, the most significant disadvantage to deep resurfacing treatments relates to the post-treatment recovery period. It may require up to several weeks or even months to fully recover and to allow the skin the form a new epidermal layer. During a period ranging from a few weeks to several weeks after a deep resurfacing treatment, the patient typically must wear heavy make-up to cover redness thus making the treatment acceptable only to women.


The superficial treatment offered by micro-dermabrasion has the advantages of being performed without anesthetics and requiring no extended post-treatment recovery period. However, micro-dermabrasion as currently practices also has several disadvantages. First, a micro-dermabrasion treatment is adapted only for a superficial exfoliation of a patient's epidermis which does not treat many forms of damage to skin. Further, the current micro-dermabrasion devices cause abrasive effects in a focused area of the skin that is very small, for example a few mm.sup.2, since all current devices use a single pin-hole orifice that jets air and abrasives to strike the skin in a highly focused area. Such a focused treatment area is suitable for superficial exfoliations when the working end of the device is passed over the skin in overlapping paths. Further, such focused energy delivery is not well suited for deeper skin removal where repeated passes may be necessary. Still further, current micro-dermabrasion devices are not suited for deeper skin removal due to the pain associated with deep abrasions. Other disadvantages of the current micro-dermabrasion devices relate to the aluminum oxide abrasive particles that are typically used. Aluminum oxide can contaminate the working environment and create a health hazard for operators and patients alike. Inhalation of aluminum oxide particles over time can result in serious respiratory disorders.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A-1B are sectional illustrations of a patient's skin showing dermal layers.



FIG. 2 is a view of a Type “A” body and working end of the instrument of the invention.



FIG. 3 is an enlarged view of the working end of the instrument of FIG. 2.



FIG. 4 is a sectional view of working end of FIG. 3.



FIG. 5 is a view showing the manner of using the working end of the invention of FIGS. 3-4 in performing a method of the invention.



FIG. 6 is a view of a Type “B” body, working end and handle in an exploded view.



FIG. 7 is a view of the working end of the instrument of FIG. 6 and a housing.



FIG. 8 is an enlarged view of the skin interface of the working end of FIG. 7.



FIG. 9 is a sectional view of the skin interface of FIG. 8.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

1. Type “A” Skin Resurfacing System. Referring to FIGS. 2-3, an exemplary instrument system 5 is shown for removing superficial skin layers. The instrument system 5 includes: (i) a hand-held body 18 with a working end 20 that defines a skin interface surface portion indicated at 25 in FIGS. 2-3. An opening portion 26 transitions into an interior passageway 28 that extends through the body to communicate with a negative (−) pressure source (or aspiration source) indicated at 30 that operates as vacuum means for aspirating skin debris from a targeted skin surface treatment site TS.


Of particular interest, FIGS. 3-4 show views of the working end 20 with the skin interface 25 being configured with a particular irregular or ridged surface structure indicated at 32. The ridged surface structure 32 further has a particular minimum width dimension W to accommodate from the ridge shape with as many as about 25 ridges on each side of opening 26 depending on the overall dimensions of the working end 20. More particular aspects of the irregular or ridged surface structure 32 will be described below.


In this preferred embodiment, the working end 20 is of any suitable material, such as a transparent medical grade plastic. The transparency of the working end will assist the operator in localizing treatment in a particular targeted skin treatment area. The overall transverse dimension of the working end 20 of FIGS. 2-3 may be from around about 5.0 mm. to about 50.0 mm. with a larger dimensioned end being adapted for treating a larger skin area (e.g., arms, back legs and decolletage). A typical dimension is from about 5.0 mm. to 15.0 mm. for a skin treatment site area TS around a patient's face.


The invention allows the area (e.g., in mm2) of opening 26 be in any selected shape but preferably is an elongate shape in the center of the working end 25. The open distal end 26 comprises the distal termination of passageway 28 and the proximal end of the passageway in handle 18 is connected to a flexible aspiration tube 33 that extends to a remote collection reservoir 35 intermediate to the actual aspiration source 30. The aspiration source 30 thus is adapted to draw the working end 20 and more particularly the skin interface 25 against the skin treatment site TS to perform the method of the invention as will be described below. The aspiration source or negative (−) pressurization source 30 may be any suitable vacuum source known in the art. Between the aspiration source 30 and remote collection reservoir 35 may be a filter 38 subsystem that is known in the art for collecting aspirated skin detritus and spent crystalline agents CA that are captured in the open distal end of passageway chamber 28. The collection reservoir 35 and filter 38 are preferably of inexpensive plastic and other materials that are disposable.


The aspiration source 30 may be provided with an adjustable valve means 40 for adjusting the pressure level setting to any suitable range. The physician will learn from experience how to balance the pressure level to attain the desired level of suction against the patient's skin. A trigger or switch component 42 is provided as a foot-switch (FIG. 2) but any suitable finger switch in the body 18 also may be used.


The working end 20 also carries means for introducing abrasive crystals into the working end or distalmost end of passageway 28 to allow individual loose crystalline agents CA to thereafter be captured between the skin interface 25 and the patient's skin. In this embodiment, two channels 44a-44b are provided together with flexible tubes 46a-46b to introduce the loose crystalline agents CA into the working end (see FIGS. 2-4). Each distal portion 47 (collectively) of the channels 44a-44b may comprise a small dimension aperture to limit the rate of flow of crystalline agents CA into the working end. The number of such channels (i.e., 44a-44n) may range from one to about ten and fall within the scope of the invention. Any singular or plural number of channels can serve the purpose of slowly introducing crystal into the working end. Referring to FIGS. 2-3, the crystalline agent CA delivery source 50 comprises a reservoir 55 that holds a suitable volume of abrasive crystals for a single treatment or a number of treatments. A flexible supply tube 56 extends between a remote the reservoir 55, and in this embodiment the tube is split to connect to the two channels 44a-44b. Preferably, the remote reservoir 55 that carries the crystalline agent CA is unpressurized but carries air intake relief valve 58 such that any slight negative pressure created by the aspiration source 30 when the skin interface is in contact with a patient's skin will draw crystals to the working end. It should be appreciated that reservoir 55 may be built into handle body 18 and fall within the scope of the invention. The crystal delivery source 50 may carry crystals ranging in size from about 1 μm to about 50 μm in maximum cross-sectional dimension, (for example, aluminum oxide crystals). Preferably, the crystals are from about 5 μm to about 30 μm in maximum cross-sectional dimension to allow a very fine abrasion of the epidermis.


It has been found that by a slight negative pressure environment the open end 26 and passageway 28, the crystalline agent will be caused to dribble into, or be sucked into, the passageway 28 in the working end 20. Thereafter, the movement of the working end 20 in a sideways movement over the skin causes a portion of the crystalline agent CA volume to be captured temporarily in the irregular or corrugated surface structure of the skin interface 25. In this process of moving the skin interface 25 over the targeted treatment site TS, it has been found that the sharp-edged crystalline agents are rolled over and over while being pressed into the surface of the skin and thereby abrade and remove the skin surface in a controllably gentle manner that is below any threshold of significant pain.


After the spent crystals are rolled over and over by the skin interface when moving in a first lateral direction across the skin, and after the working end is then is reversed in directional movement across the skin, a portion of the spent crystals and abraded skin debris necessarily roll into the central opening portion 26 wherein the negative pressure environment captures and aspirates the abraded materials to the remote collection reservoir 35.


To facilitate the process described above, the invention is provided with novel aspects that relate to the irregular or ridged surface structure 32 mentioned above. The entire skin interface 25 may be of any suitable plan form (e.g., round, oval, rectangular etc.) and fall within the scope of the invention. More in particular, the interface 25 defines a 1st outer periphery 25A and a 2nd inner periphery 25B that generally are in apposition to one another and are spaced apart by width W with the inner periphery about the edge of opening 26 (see FIG. 3).


In a preferred embodiment shown in FIGS. 3-4, the concept of 1st and 2nd peripheries 25A and 25B in apposition thus comprise peripheries that are dual and side-by-side as shown in FIG. 4 and are thus adapted for side-to-side lateral or sideways movement while performing the technique of the invention, for example which is a natural movement of a human hand over a patient's skin. Thus, the direction of the ridges 60 extend generally transverse relative to a line drawn that indicates the direction of movement of the working end 20 in performing the method of the invention. That is, in the exemplary working end of FIG. 4, the working end is generally optimized for side-to-side or lateral movement. Thus, the ridge alignment is generally transverse to the direction of movement in operations indicated by arrow A. (In a circular working end that is adapted generally for movement is any direction, the direction of the ridges 60 may be generally transverse to any direction of movement by being concentric relative to a central opening 26 (not shown)).


The terms irregular or ridged shape structure 32 as used herein mean that a series of at least one projecting edge portion 62a projects distally as a ridge within the skin interface portion 25. The irregular shape structure 32 further typically carries recessed portions or valley portions 62b that are recessed in the proximal direction intermediate to any plurality of projecting edge portions 62a. These surface configurations for convenience are herein termed the primary shape structure (or ridge and valley elements). The width of the skin interface 25 containing shape structure 32 may be from about 2.0 mm. to 25.0 mm. or more and preferably is from about 3.0 mm. to 10.0 mm. The number of ridges preferably are from about 1 ridge to 25 ridges on each side of the opening 26. The height H of any ridge from the apex of the projecting portion 62a to the depth of the valley portion 62b may be from about 0.25 mm. to about 5.0 mm. and is preferably from about 0.5 mm. to about 2.0 m. It has been found that various ridge height dimensions are optimal depending on the patient's skin type. Further, but optionally, it has been found that secondary shape structure of notches or recessed grooves 66 configured across the primary shape structure of ridge and valley elements may help introduce loose crystals to regions of the skin interface 25 in contact with the skin which is desirable. Such secondary grooves 66 are shown in FIG. 4 and are preferably somewhat in alignment with an axis of channels 44a-44b that introduce crystals into the working end 20 thus allowing the crystals to be suctioned into the valleys 62b of the primary shape structure.


While the series of primary ridge and valley elements together the secondary grooves seems to be optimal for the method described below, it should be appreciated that the method also may be performed with a skin interface that has (i) only primary ridge and valley elements; (ii) or only a particular surface roughness that is appropriate for partially capturing loose crystals as will be described below-as long as the skin interface has a minimum width of about 3.0 mm. which was described as a preferred width dimension previously.



FIG. 4 further shows that at least some of the crests or apexes of some of the ridge portions 62a together with the outermost periphery of the skin interface 25 define an overall tissue-receiving shape 64 that may range from flat to concave and is shown in a preferred concave configuration. The alternative shapes 64a-44b are intended to indicate an approximate range of shapes that are suitable. The apexes of ridges 62a need not all be at the same height to define shape 64. The purpose of the concave shape is to cause the outer periphery of the working end to be in firm contact with the tissue surface while the negative pressure from aspiration source 30 draws the skin into firm contact with tissue interface 25.


2. Practice of the Method of the Invention. Now turning to FIG. 5, a sectional view of working end 20 shows the technique of the present invention in exfoliating or removing skin surface layers. FIG. 5 shows the working end 20 after actuation of the negative (−) pressure source 30 with the skin surface 70 initially being drawn into the concave shape 64. The operating negative pressures may be in any suitable range that is determined by investigation. It has been found by experimentation that optimal pressure levels vary greatly depending on (i) the type of skin targeted for treatment, (ii) the dimensions across the working end, and (iii) the dimensions of opening 26.


Next, the operator moves the skin interface 25 across a treatment site TS which is a path on the patient's skin while still actuating moves the trigger 42 thereby maintaining the negative pressure environment in the passageway 26. The negative pressure environment within the working end causes crystalline particles and entrained in air to be drawn into passageway 28 proximate to the skin surface and into the shape structure 32 of the skin interface 25. The sideways or lateral movement of the skin interface 25 captures a portion of the crystals between the interface and the skin surface, in part by over-rolling them. The continued rolling of the sharp-edged crystals trapped between the instrument and the skin surface 70 causes an abrasion and removal of the skin surface in a controllable manner.


As working end is moved in a reverse direction, the negative pressure environment in the passageway 28 captures and aspirates the spent crystals and skin debris to the remote collection reservoir 35. At the end of a particular lateral movement of the working end, the operator may release the trigger 42 which terminates the crystal agent delivery and further allows the operator to easily lift the working end from the patient's skin. The treated path can be easily seen and the operator then can exfoliate another slightly overlapping or adjacent path by repeating the above steps until surface removal is completed over the targeted treatment area.


3. Type “B” Skin Resurfacing System. Referring to FIGS. 6-9, another exemplary instrument system and treatment device 205 is shown for removing superficial skin layers. This system differs greatly from the Type “A” embodiment in the mechanism of action that abrades the skin since the Type “B” system uses a fluid media plus an abrading structure on the skin interface. Still several features of the Type “B” embodiment are similar to the Type “A” embodiment and the two modalities of treatment may be used to complement one another.



FIG. 6 shows that a hand-held instrument 208 has a removable working end 220 that defines a skin interface surface portion indicated at 225. Handle portion 227a mates with housing 227b. A flexible tube 228 extends to a vacuum source 230. A fluid reservoir 235 carrying a fluid skin treatment media is housed in the handle although it could also be a remote reservoir.


Referring now to FIGS. 7-9, a first aperture arrangement consisting of at least one port or opening portion 240 of skin interface 225 that communicates with an interior passageway 242 that extends through housing 227b to hose 228 and the vacuum or negative (−) pressure source.



FIGS. 7-9 further show a second aperture arrangement in the skin interface consisting of at least one port or openings 250 that extend around an outer periphery of the skin interface 225. These opening(s) of the second aperture arrangement are in fluid communication with the reservoir 235 and the treatment media therein. The skin interface has a series of primary ridge elements 255a and valley elements 255b together the secondary notches or grooves 260 as defined above with similar dimensional parameters. This embodiment differs however in that the apexes of ridge elements 255a are substantially a sharp edge as are the edged of the notches 260. Thus, these primary surface elements 255a and secondary surface elements thereby define teeth therebetween that seem well suited to abrading skin layers particularly after being hydrated by the fluid source of the system. Experimentation has shown that the vacuum source and fluid source may be reversed between the first and second aperture arrangements 240 and 250 with the method of skin removal still working well. The vacuum system aspirates away skin debris and spent fluids as described previously. Of particular interest, the method of the invention appears to work well because the suction on the skin treatment site very quickly hydrated, or puffs up, the skin which in turn make the surface layer susceptible to painless abrasion. The ability of the system to rapidly deliver fluids to subsurface tissues allows the use of any pharmacological agent known in the art for enhancing skin rejuvenation as a part of the skin treatment. The system can use sterile water or saline solution for a treatment to remove dermal tissue with the abrasive surface of the treatment device. The system can also use a fluid carrying a chemical agent of a suitable concentration be selected from a group of acids including TCA (trichloroacetic acid), a glycolic acid including an alphahydroxy acid (AHA), a lactic acid, a citric acid, or phenol as disclosed in co-pending U.S. patent application Ser. No. 09/524,731 filed Mar. 14, 2000 which is incorporated herein by this reference.


Specific features of the invention may be shown in some figures and not in others, and this is for convenience only and any feature may be combined with another in accordance with the invention. While the principles of the invention have been made clear in the exemplary embodiments, it will be obvious to those skilled in the art that modifications of the structure, arrangement, proportions, elements, and materials may be utilized in the practice of the invention, and otherwise, which are particularly adapted to specific environments and operative requirements without departing from the principles of the invention. The appended claims are intended to cover and embrace any and all such modifications, with the limits only of the true purview, spirit and scope of the invention.

Claims
  • 1. A handheld device for treating a skin surface, comprising: a body comprising a housing;a working end portion positioned along a first end of the body, the working end portion comprising a distal end configured to contact a skin surface, wherein the working end portion comprises a perimeter along the distal end configured to contact the skin surface, a skin interface positioned along the interior of the perimeter, wherein the skin interface is configured to contact the skin surface during use;a first aperture arrangement comprising at least one first port located along or near the working end portion, the at least one first port being in fluid communication with a vacuum source via at least one waste passageway extending through the housing; anda second aperture arrangement comprising at least one second port located along or near the working end portion, the at least one second port being in fluid communication with a hydration treatment media source;wherein the vacuum source is configured to create a vacuum within the at least one waste passageway and the working end portion, and wherein the vacuum source is configured to simultaneously deliver a treatment media from the hydration treatment media source to the working end portion and remove spent treatment media away from the working end portion via the at least one waste passageway;wherein, when the vacuum source is activated and the working end portion of the device is positioned along a skin surface, hydration treatment media is delivered to the skin surface through the at least one passageway and the at least one second port due to the vacuum generated along the working end portion by the vacuum source, and spent treatment media is, at least partially, simultaneously aspirated away from the working end portion through the at least one first port by the same suction force generated by the vacuum source.
  • 2. The device of claim 1, wherein the at least one passageway extends at least partially through an interior of the housing.
  • 3. The device of claim 1, further comprising a filter located between the working end portion and the vacuum source.
  • 4. The device of claim 1, wherein the working end portion is removably positioned along a distal end of the housing.
  • 5. The device of claim 1, wherein the working end portion comprises plastic.
  • 6. The device of claim 1, wherein the working end portion is at least partially transparent.
  • 7. The device of claim 1, wherein, when in use, the vacuum source draws skin through an aperture defined by the perimeter of the working end portion to facilitate contact between the working end portion and the skin surface.
  • 8. The device of claim 1, wherein the at least one passageway comprises a conduit that extends proximally from the housing of the device to the vacuum source.
  • 9. The device of claim 1, further comprising a vacuum source.
  • 10. The device of claim 1, wherein the at least one second port is in fluid communication with the hydration treatment media source via a treatment media passageway.
  • 11. The device of claim 1, wherein the hydration treatment media source is separate from to the handheld device.
  • 12. The device of claim 1, wherein the hydration treatment media source comprises a reservoir.
  • 13. A system for treating a skin surface, comprising: a hydration treatment media source;a handheld device comprising: a body comprising a housing;a working end portion positioned along a first end of the body, the working end portion comprising a distal end configured to contact the skin surface, wherein the working end portion comprises a perimeter along the distal end configured to contact the skin surface, a skin interface positioned along the interior of the perimeter, wherein the skin interface is configured to contact the skin surface during use;a first aperture arrangement comprising at least one first port located along or near the working end portion; anda second aperture arrangement comprising at least one second port located along or near the working end portion, the at least one second port being in fluid communication with the treatment media source; anda single vacuum source in fluid communication with the at least one first port via at least one passageway;wherein, when the single vacuum source is activated and the working end portion of the device is positioned along a skin surface, a hydration treatment media is delivered to the skin surface through the at least one passageway and the at least one second port, and spent treatment media is simultaneously, at least partially, aspirated away from the working end portion through the at least one first port.
  • 14. The system of claim 13, wherein, when in use, the vacuum source draws skin through an aperture defined by the perimeter of the working end portion to facilitate contact between the working end portion and the skin surface.
  • 15. The system of claim 13, wherein the at least one second port is in fluid communication with the hydration treatment media source via a treatment media passageway.
  • 16. The system of claim 13, wherein the hydration treatment media source is separate from to the handheld device.
  • 17. The system of claim 13, wherein the hydration treatment media source comprises a reservoir, and wherein the reservoir is separate from to the handheld device and is in fluid communication with the handheld device using at least one treatment media conduit.
  • 18. The system of claim 13, wherein the hydration treatment media comprises at least one of the following: water, saline, a chemical agent and an acid.
  • 19. The device of claim 13, wherein a reservoir is housed in the handheld device.
  • 20. The device of claim 1, wherein a reservoir containing the hydration treatment media source is housed in the housing of the body.
  • 21. The device of claim 1, wherein the skin interface comprises ridge and valley elements.
  • 22. The device of claim 1, wherein the skin interface comprises an irregular or ridged surface structure.
  • 23. The device of claim 1, wherein the working end portion comprises a medical grade plastic.
  • 24. The device of claim 1, wherein the working end portion is transparent.
  • 25. The device of claim 13, wherein the skin interface comprises ridge and valley elements.
  • 26. The device of claim 13, wherein the skin interface comprises an irregular or ridged surface structure.
  • 27. The device of claim 13, wherein the working end portion comprises a medical grade plastic.
  • 28. The device of claim 13, wherein the working end portion is transparent.
PRIORITY INFORMATION

This application is a continuation of U.S. patent application Ser. No. 13/620,164, filed Sep. 14, 2012, which is a continuation of U.S. patent application Ser. No. 11/739,615, filed Apr. 24, 2007, now U.S. Pat. No. 8,337,513, which is a divisional of U.S. patent application Ser. No. 10/699,747, filed Nov. 3, 2003, now U.S. Pat. No. 7,789,886, which is a continuation of U.S. patent application Ser. No. 09/648,025 filed Aug. 25, 2000, now U.S. Pat. No. 6,641,591, which claims the priority benefit under 35 U.S.C. §119(e) of Provisional U.S. patent application No. 60/150,782, filed Aug. 26, 1999, the entire contents of these applications being hereby incorporated by reference herein.

US Referenced Citations (367)
Number Name Date Kind
2608032 Garver Aug 1952 A
2631583 Lavergne Mar 1953 A
2701559 Cooper Feb 1955 A
2712823 Kurtin Jul 1955 A
2867214 Wilson Jan 1959 A
2881763 Robbins Apr 1959 A
2921585 Schumann Jan 1960 A
3085573 Meyer et al. Apr 1963 A
3214869 Stryker Nov 1965 A
3476112 Elstein Nov 1969 A
3574239 Sollerud Apr 1971 A
3715838 Young et al. Feb 1973 A
3865352 Nelson et al. Feb 1975 A
3866264 Engquist Feb 1975 A
3948265 Al Ani Apr 1976 A
3964212 Karden Jun 1976 A
3977084 Sloan Aug 1976 A
4121388 Wilson Oct 1978 A
4155721 Fletcher May 1979 A
4170821 Booth Oct 1979 A
4182329 Smit et al. Jan 1980 A
4203431 Abura et al. May 1980 A
4216233 Stein Aug 1980 A
4299219 Norris, Jr. Nov 1981 A
4378804 Cortese Apr 1983 A
4560373 Sugino et al. Dec 1985 A
4646480 Williams Mar 1987 A
4646482 Chitjian Mar 1987 A
4655743 Hyde Apr 1987 A
4676749 Mabille Jun 1987 A
4706676 Peck Nov 1987 A
4754756 Shelanski Jul 1988 A
4757814 Wang et al. Jul 1988 A
4764362 Barchas Aug 1988 A
4795421 Blasius, Jr. et al. Jan 1989 A
4836192 Abbate Jun 1989 A
4875287 Creasy et al. Oct 1989 A
4886078 Shiffman Dec 1989 A
4887994 Bedford Dec 1989 A
4900316 Yamamoto Feb 1990 A
4917086 Feltovich et al. Apr 1990 A
4925450 Imonti et al. May 1990 A
4957747 Stiefel Sep 1990 A
5006004 Dirksing et al. Apr 1991 A
5006339 Bargery et al. Apr 1991 A
5012797 Liang et al. May 1991 A
5035089 Tillman et al. Jul 1991 A
5037431 Summers Aug 1991 A
5037432 Molinari Aug 1991 A
5100412 Rosso Mar 1992 A
5100424 Jang Mar 1992 A
5119839 Rudolph Jun 1992 A
5122153 Harrel Jun 1992 A
5207234 Rosso May 1993 A
5222956 Waldron Jun 1993 A
5242433 Smith et al. Sep 1993 A
5254109 Smith et al. Oct 1993 A
5368581 Smith et al. Nov 1994 A
5391151 Wilmot Feb 1995 A
5417674 Smith et al. May 1995 A
5419772 Teitz et al. May 1995 A
5460620 Smith et al. Oct 1995 A
5470323 Smith et al. Nov 1995 A
5484427 Gibbons Jan 1996 A
5562642 Smith et al. Oct 1996 A
5611687 Wagner Mar 1997 A
5612797 Clarke Mar 1997 A
5674235 Parisi Oct 1997 A
5676643 Cann et al. Oct 1997 A
5676648 Henley Oct 1997 A
5683971 Rose et al. Nov 1997 A
5697920 Gibbons Dec 1997 A
5707383 Bays et al. Jan 1998 A
5713785 Nishio Feb 1998 A
5735833 Olson Apr 1998 A
5759185 Grinberg Jun 1998 A
5779519 Oliver Jul 1998 A
5800446 Banuchi Sep 1998 A
5807353 Schmitz Sep 1998 A
5810842 Di Fiore et al. Sep 1998 A
5813416 Rudolph Sep 1998 A
5817050 Klein Oct 1998 A
5846215 Zygmont Dec 1998 A
5848998 Marasco, Jr. Dec 1998 A
5861142 Schick Jan 1999 A
5873881 McEwen et al. Feb 1999 A
5879323 Henley Mar 1999 A
5882201 Salem Mar 1999 A
5885260 Mehl, Sr. et al. Mar 1999 A
5908401 Henley Jun 1999 A
5919152 Zygmont Jul 1999 A
5954730 Bernabei Sep 1999 A
5971999 Naldoni Oct 1999 A
5980555 Barbut et al. Nov 1999 A
6019749 Fields et al. Feb 2000 A
6024733 Eggers et al. Feb 2000 A
6027402 Oliver Feb 2000 A
6039745 Di Fiore et al. Mar 2000 A
6042552 Cornier Mar 2000 A
6080165 DeJacma Jun 2000 A
6080166 McEwen et al. Jun 2000 A
6090085 Mehl, Sr. et al. Jul 2000 A
6120512 Bernabei Sep 2000 A
6129701 Cimino Oct 2000 A
6136008 Becker et al. Oct 2000 A
6139553 Dotan Oct 2000 A
6139554 Karkar et al. Oct 2000 A
6142155 Rudolph Nov 2000 A
6149634 Bernabei Nov 2000 A
6159226 Kim Dec 2000 A
6162218 Elbrecht et al. Dec 2000 A
6162232 Shadduck Dec 2000 A
6183451 Mehl, Sr. et al. Feb 2001 B1
6183483 Chang Feb 2001 B1
6193589 Khalaj Feb 2001 B1
6231593 Meserol May 2001 B1
6235039 Parkin et al. May 2001 B1
6238275 Metcalf et al. May 2001 B1
6241739 Waldron Jun 2001 B1
6264666 Coleman et al. Jul 2001 B1
6277128 Muldner Aug 2001 B1
6283978 Cheski et al. Sep 2001 B1
6299620 Shadduck Oct 2001 B1
6306119 Weber et al. Oct 2001 B1
6306147 Bernabei et al. Oct 2001 B1
6322568 Bernabei et al. Nov 2001 B1
6368333 Bernabei et al. Apr 2002 B2
6387103 Shadduck May 2002 B2
6401289 Herbert Jun 2002 B1
6409736 Bernabei Jun 2002 B1
6410599 Johnson Jun 2002 B1
RE37796 Henley Jul 2002 E
6414032 Johnson Jul 2002 B1
6420431 Johnson Jul 2002 B1
6423078 Bays et al. Jul 2002 B1
6423750 Johnson Jul 2002 B1
6432113 Parkin et al. Aug 2002 B1
6432114 Rosso Aug 2002 B1
6471712 Burres Oct 2002 B2
6477410 Henley et al. Nov 2002 B1
6482212 Bernabei et al. Nov 2002 B1
6488646 Zygmont Dec 2002 B1
6494856 Zygmont Dec 2002 B1
6500183 Waldron Dec 2002 B1
6503256 Parkin et al. Jan 2003 B2
6511486 Mercier et al. Jan 2003 B2
6514262 Di Fiore et al. Feb 2003 B1
6527783 Ignon Mar 2003 B1
6535761 Bernabei Mar 2003 B2
6540757 Hruska et al. Apr 2003 B1
6562013 Marasco, Jr. May 2003 B1
6562050 Owen May 2003 B1
6564093 Ostrow et al. May 2003 B1
6565535 Zaias et al. May 2003 B2
6582442 Simon et al. Jun 2003 B2
6589218 Garcia Jul 2003 B2
6592595 Mallett et al. Jul 2003 B1
6629983 Ignon Oct 2003 B1
6641591 Shadduck Nov 2003 B1
6645184 Zelickson et al. Nov 2003 B1
6652888 Rhoades Nov 2003 B2
6673081 Tavger et al. Jan 2004 B1
6673082 Mallett et al. Jan 2004 B2
6685853 Angelopoulos et al. Feb 2004 B1
6687537 Bernabei Feb 2004 B2
6695853 Karasiuk Feb 2004 B2
6735470 Henley et al. May 2004 B2
6743211 Prausnitz et al. Jun 2004 B1
6743215 Bernabei Jun 2004 B2
6764493 Weber et al. Jul 2004 B1
6869611 Kligman et al. Mar 2005 B1
6905487 Zimmerman Jun 2005 B2
6911031 Muldner Jun 2005 B2
6924649 Knoedgen Aug 2005 B2
6926681 Ramey et al. Aug 2005 B1
6942649 Ignon et al. Sep 2005 B2
7001355 Nunomura et al. Feb 2006 B2
7004933 McDaniel Feb 2006 B2
7044938 La Bianco et al. May 2006 B2
7052503 Bernabei May 2006 B2
7069073 Henley et al. Jun 2006 B2
7070488 Suissa et al. Jul 2006 B2
7083580 Bernabei Aug 2006 B2
7087063 Carson et al. Aug 2006 B2
7094252 Koop Aug 2006 B2
7115275 Clarot et al. Oct 2006 B2
7135011 Powers et al. Nov 2006 B2
7153311 Chung Dec 2006 B2
7197359 Tokudome et al. Mar 2007 B1
7198623 Fischer et al. Apr 2007 B2
7232444 Chang Jun 2007 B2
7241208 Suissa et al. Jul 2007 B2
7276051 Henley et al. Oct 2007 B1
7314326 Rosenberg Jan 2008 B2
7316657 Kleinhenz et al. Jan 2008 B2
7318828 Revivo Jan 2008 B1
7320691 Pilcher et al. Jan 2008 B2
7320801 Kelly Jan 2008 B2
7354423 Zelickson et al. Apr 2008 B2
7364565 Freeman Apr 2008 B2
7384405 Rhoades Jun 2008 B2
7427273 Mitsui Sep 2008 B2
7458944 Liste et al. Dec 2008 B2
7476205 Erdmann Jan 2009 B2
7477938 Sun et al. Jan 2009 B2
7482314 Grimes et al. Jan 2009 B2
7489989 Sukhanov et al. Feb 2009 B2
7507228 Sun et al. Mar 2009 B2
7582067 Van Acker Sep 2009 B2
7597900 Zimmer et al. Oct 2009 B2
7597901 Clarot et al. Oct 2009 B2
7658742 Karasiuk Feb 2010 B2
7678120 Shadduck Mar 2010 B2
7744582 Sadowski et al. Jun 2010 B2
7789886 Shadduck Sep 2010 B2
7837695 Hart et al. Nov 2010 B2
7901373 Tavger Mar 2011 B2
7951156 Karasiuk May 2011 B2
8025669 David et al. Sep 2011 B1
RE42960 Waldron Nov 2011 E
8048089 Ignon et al. Nov 2011 B2
8066716 Shadduck Nov 2011 B2
8088085 Thiebaut et al. Jan 2012 B2
8128638 Karasiuk et al. Mar 2012 B2
8221437 Waldron et al. Jul 2012 B2
8236008 Boone, III et al. Aug 2012 B2
8277287 Hart Oct 2012 B2
8337513 Shadduck Dec 2012 B2
8343116 Ignon et al. Jan 2013 B2
8814836 Ignon et al. Aug 2014 B2
9056193 Ignon et al. Jun 2015 B2
9468464 Shadduck Oct 2016 B2
9474886 Ignon et al. Oct 2016 B2
9486615 Ignon et al. Nov 2016 B2
9498610 Ignon et al. Nov 2016 B2
9550052 Ignon et al. Jan 2017 B2
9566088 Ignon et al. Feb 2017 B2
9642997 Ignon et al. May 2017 B2
9662482 Ignon et al. May 2017 B2
20010023351 Eilers Sep 2001 A1
20010037118 Shadduck Nov 2001 A1
20010049511 Coleman et al. Dec 2001 A1
20020016601 Shadduck Feb 2002 A1
20020041891 Cheski Apr 2002 A1
20020058952 Weber et al. May 2002 A1
20020107527 Burres Aug 2002 A1
20020128663 Mercier et al. Sep 2002 A1
20020133110 Citow Sep 2002 A1
20020133176 Parkin et al. Sep 2002 A1
20020151826 Ramey et al. Oct 2002 A1
20020151908 Mallett, Sr. et al. Oct 2002 A1
20020188261 Hruska Dec 2002 A1
20030012415 Cossel Jan 2003 A1
20030018252 Duchon et al. Jan 2003 A1
20030060834 Muldner Mar 2003 A1
20030093040 Mikszta et al. May 2003 A1
20030093089 Greenberg May 2003 A1
20030097139 Karasiuk May 2003 A1
20030167032 Ignon Sep 2003 A1
20030187462 Chang Oct 2003 A1
20030208159 Ignon et al. Nov 2003 A1
20030212127 Glassman et al. Nov 2003 A1
20030212415 Karasiuk Nov 2003 A1
20040010222 Nunomura et al. Jan 2004 A1
20040010269 Grimes et al. Jan 2004 A1
20040015139 La Bianco Jan 2004 A1
20040087972 Mulholland et al. May 2004 A1
20040092895 Harmon May 2004 A1
20040092959 Bernaz May 2004 A1
20040097967 Ignon May 2004 A1
20040122447 Harmon et al. Jun 2004 A1
20040127914 Chung Jul 2004 A1
20040143274 Shadduck Jul 2004 A1
20040162565 Carson et al. Aug 2004 A1
20040166172 Rosati et al. Aug 2004 A1
20040219179 McDaniel Nov 2004 A1
20040236291 Zelickson et al. Nov 2004 A1
20040243149 Lee, Jr. Dec 2004 A1
20040254587 Park Dec 2004 A1
20040267285 Chang Dec 2004 A1
20050037034 Rhoades Feb 2005 A1
20050038448 Chung Feb 2005 A1
20050059940 Weber et al. Mar 2005 A1
20050084509 Bernstein Apr 2005 A1
20050148958 Rucinski Jul 2005 A1
20050203111 David Sep 2005 A1
20050209611 Greenberg Sep 2005 A1
20050283176 Law Dec 2005 A1
20060002960 Zoeteweij et al. Jan 2006 A1
20060116674 Goble et al. Jun 2006 A1
20060161178 Lee Jul 2006 A1
20060189964 Anderson Aug 2006 A1
20060191562 Nunomura Aug 2006 A1
20060200099 La Bianco et al. Sep 2006 A1
20060200172 Shadduck Sep 2006 A1
20060200173 Shadduck Sep 2006 A1
20060212029 Arcusa Villacampa et al. Sep 2006 A1
20060253125 Ignon Nov 2006 A1
20060264893 Sage, Jr. et al. Nov 2006 A1
20070005078 Hart et al. Jan 2007 A1
20070043382 Cheney Feb 2007 A1
20070065515 Key Mar 2007 A1
20070088371 Karasiuk Apr 2007 A1
20070123808 Rhoades May 2007 A1
20070154502 Hattendorf et al. Jul 2007 A1
20070156124 Ignon et al. Jul 2007 A1
20070178121 First et al. Aug 2007 A1
20070198031 Kellogg Aug 2007 A1
20070208353 Shadduck Sep 2007 A1
20070239173 Khalaj Oct 2007 A1
20080027328 Klopotek et al. Jan 2008 A1
20080091179 Durkin et al. Apr 2008 A1
20080103563 Powell May 2008 A1
20080119781 King May 2008 A1
20080132914 Bossard et al. Jun 2008 A1
20080139974 Da Silva Jun 2008 A1
20080154161 Abbott Jun 2008 A1
20080193493 Rhoades Aug 2008 A1
20080200861 Shalev et al. Aug 2008 A1
20080208146 Brandwein et al. Aug 2008 A1
20080214987 Xu Sep 2008 A1
20080215068 Hart et al. Sep 2008 A1
20080221548 Danenberg et al. Sep 2008 A1
20080243039 Rhoades Oct 2008 A1
20080287864 Rosenberg Nov 2008 A1
20080300529 Reinstein Dec 2008 A1
20080300552 Cichocki et al. Dec 2008 A1
20090048557 Yeshurun et al. Feb 2009 A1
20090053390 Sakou et al. Feb 2009 A1
20090062815 Karasiuk et al. Mar 2009 A1
20090099091 Hantash Apr 2009 A1
20090099093 Hantash Apr 2009 A1
20090124985 Hasenoehrl et al. May 2009 A1
20090138026 Wu May 2009 A1
20090177171 Ignon et al. Jul 2009 A1
20090192442 Ignon et al. Jul 2009 A1
20090222023 Boone, III et al. Sep 2009 A1
20100045427 Boone, III et al. Feb 2010 A1
20100049177 Boone, III et al. Feb 2010 A1
20100049210 Boone, III et al. Feb 2010 A1
20100217357 Da Silva Aug 2010 A1
20100305495 Anderson et al. Dec 2010 A1
20110054490 Hart Mar 2011 A1
20110066162 Cohen Mar 2011 A1
20110082415 Ignon et al. Apr 2011 A1
20120022435 Ignon et al. Jan 2012 A1
20120041338 Chickering, III et al. Feb 2012 A1
20120136374 Karasiuk May 2012 A1
20130018317 Bobroff et al. Jan 2013 A1
20130066336 Boone, III et al. Mar 2013 A1
20130096577 Shadduck Apr 2013 A1
20130102978 Ignon et al. Apr 2013 A1
20130144280 Eckhouse et al. Jun 2013 A1
20130158547 David Jun 2013 A1
20140343481 Ignon Nov 2014 A1
20140343574 Ignon et al. Nov 2014 A1
20150032047 Ignon et al. Jan 2015 A1
20150230824 Shadduck Aug 2015 A1
20150230825 Shadduck Aug 2015 A1
20150231379 Ignon et al. Aug 2015 A1
20150265822 Ignon et al. Sep 2015 A1
20150272623 Ignon et al. Oct 2015 A1
20150290442 Ignon et al. Oct 2015 A1
20160038183 Ignon et al. Feb 2016 A1
20160256671 Ignon et al. Sep 2016 A1
20170036002 Ignon et al. Feb 2017 A1
20170065801 Ignon et al. Mar 2017 A1
Foreign Referenced Citations (28)
Number Date Country
34 21 390 Dec 1985 DE
234 608 Apr 1986 DE
10 2004 015815 Nov 2005 DE
0 258 901 Sep 1987 EP
0 564 392 Mar 1993 EP
2106780 Mar 2016 EP
553 076 Dec 1956 IT
118 49 22 Mar 1985 IT
1993-088552 Dec 1993 JP
09-294747 Nov 1997 JP
2003-534881 Nov 2003 JP
2003-339713 Dec 2003 JP
2004-275721 Oct 2004 JP
2006-503627 Feb 2006 JP
2006-204767 Oct 2006 JP
20-0280320 Jul 2002 KR
WO 9711650 Mar 1997 WO
WO 0015300 Mar 2000 WO
WO 0193931 Dec 2001 WO
WO 03073917 Sep 2003 WO
WO 2004037098 May 2004 WO
WO 2005070313 Aug 2005 WO
WO 2004037098 Feb 2006 WO
WO 2006018731 Feb 2006 WO
WO 2007114904 Oct 2007 WO
WO 2009088884 Jul 2009 WO
WO 2009097451 Aug 2009 WO
WO 2012145667 Oct 2012 WO
Non-Patent Literature Citations (7)
Entry
Ex Parte Reexamination Certificate U.S. Pat. No. 6,241,739 C1, Microdermabrasion Device and Method of Treating the Skin Surface, Inventor Stephen H. Waldron, Dec. 11, 2007, and file history through Aug. 8, 2006.
File History of Reissue U.S. Appl. No. 11/027,590, filed Dec. 29, 2004 (Reissue of U.S. Pat. No. 6,500,183, issued Dec. 31, 2002).
File History of Reexamination No. 90/007,683 (Reexamination of U.S. Pat. No. 6,241,739, issued Jun. 5, 2001).
Cox III et al., Decreased Splatter in Dermabrasion, Arch Facial Plastic Surgery, Jan.-Mar. 2000, vol. 2, pp. 23-26.
Ditre et al., Effect of a-hydroxy acids on photoaged skin: A pilot clinical, histologic, and ultrastructural study, Journal of American Academy of Dermatology, Feb. 1996, vol. 34, No. 2, Part 1, pp. 187-195.
Harris et al., Combining Manual Dermasanding with Low Strength Trichloroacetic Acid to Improve Antinically Injured Skin, The Journal of Dermatologic Surgery and Oncology, Jul. 1994, vol. 20, No. 7, pp. 436-442.
File History of Reexamination No. 90/013,284 filed Jul. 2, 2014 (Reexamination of U.S. Pat. No. 6,241,739, dated Jun. 5, 2001).
Related Publications (1)
Number Date Country
20150230825 A1 Aug 2015 US
Provisional Applications (1)
Number Date Country
60150782 Aug 1999 US
Divisions (1)
Number Date Country
Parent 10699747 Nov 2003 US
Child 11739615 US
Continuations (3)
Number Date Country
Parent 13620164 Sep 2012 US
Child 14702509 US
Parent 11739615 Apr 2007 US
Child 13620164 US
Parent 09648025 Aug 2000 US
Child 10699747 US